Arthneeti
All Q2 FY27 results →
SA

Solara Active Pharma Sciences Ltd

Q2 FY27

Solara Active Pharma Sciences Q2 FY27 results statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and projects.

Price₹697
Market cap₹3.4K Cr
P/E791.9
Updated16 Oct 2026
Read4 min read

Based on Solara Active Pharma Sciences Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Revenue from operations for the quarter ended September 30, 2026, is Rs. EBITDA for the quarter ended Sept 30, 2026: Rs.

From Solara Active Pharma Sciences Ltd's Q2 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • Revenue from operations for the quarter ended September 30, 2026, is Rs. 417.34 Crores, up from Rs. 313.54 Crores in the corresponding quarter of the previous year, reflecting a year-on-year increase of about 33.1%.
  • Total income (including other income) for the quarter is Rs. 417.57 Crores vs. Rs. 314.03 Crores year-on-year.
  • The presentation does not state any explicit outlook or guidance for future revenue or volume growth within the provided pages.

2 more points from Solara Active Pharma Sciences Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Solara Active Pharma Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation mentions the following capex, capacity expansions, or new projects: - Capital expenditure for property, plant, equipment, and intangible assets was Rs. 154.83 crores in the six months ended September 30, 2026 (Standalone cash flow statement, Page 11). - Capital work in progress as of September 30, 2026, was Rs. 207.64 crores (Standalone Balance Sheet, Page 10). - Right of use assets and lease liabilities related to plants are recorded but specific expansions or new plants are not detailed.

2 more points from Solara Active Pharma Sciences Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

See what Solara Active Pharma Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The presentation does not explicitly report or mention any details about order book, order inflow, or pending orders. The provided pages contain the following information: - Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. - Standalone and consolidated balance sheets as at September 30, 2026 and March 31, 2026. - Standalone statement of cash flows for the six months period ended September 30, 2026 and 2025. - Independent auditor’s review reports on the standalone and consolidated financial results.

2 more points from Solara Active Pharma Sciences Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY27)

    Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj

  • Himalaya Nutravedics (Q2 FY27)

    Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese

  • Granules India (Q2 FY27)

    Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…

  • Accent Microcell (Q2 FY27)

    . Key investor presentation takeaways from Accent Microcell Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Solara Active Pharma Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Solara Active Pharma Sciences Ltd Q2 FY27 results?

Revenue from operations for the quarter ended September 30, 2026, is Rs. EBITDA for the quarter ended Sept 30, 2026: Rs.

What is Solara Active Pharma Sciences Ltd share price analysis?

Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 791.9 with a market cap of ₹3,381 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active Pharma Sciences Ltd planning capital expenditure?

The results statement mentions the following capex, capacity expansions, or new projects: - Capital expenditure for property, plant, equipment, and intangible assets was Rs.

Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.